# Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

> **NCT03568383** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 5832 (actual)

## Conditions studied

- Tuberculosis, MDR

## Interventions

- **DRUG:** Delamanid (DLM)
- **DRUG:** Isoniazid (INH)
- **DIETARY_SUPPLEMENT:** Pyridoxine (vitamin B6)

## Key facts

- **NCT ID:** NCT03568383
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-03
- **Primary completion:** 2027-01-11
- **Final completion:** 2027-01-11
- **Target enrollment:** 5832 (ACTUAL)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568383, "Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03568383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*